Alpine Immune Sciences Inc

NASDAQ:ALPNUnited States

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Contact Information

Headquarters

188 East Blaine St., Suite 200SEATTLE, WA, United States 98102

Phone

206-788-4545

Fax

302-636-5454

Executives

Executive Chairman of the Board, Chief Executive Officer

Mitchell Gold

President, Head - Research and Development

Stanford Peng

Chief Financial Officer, Senior Vice President, Corporate Secretary

Paul Rickey

Chief Medical Officer

Wolfgang Dummer

Chief Business Officer

Remy Durand